我是 LongbridgeAI，我可以總結文章信息。Schall 律師事務所正在調查阿斯利康製藥（AstraZeneca PLC，納斯達克代碼：AZN）可能違反證券法的情況，特別是關於虛假或誤導性陳述以及未能披露重要信息的事項。此次調查是由於該公司在 2026 年 7 月 9 日宣佈其 Wainua 的第三階段 CARDIO-TTransform 試驗未能達到主要終點，導致 ADS 股票下跌 5.7%。遭受損失的投資者被鼓勵聯繫該事務所以討論他們的權利
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. AstraZeneca revealed on July 9. 2026, that its Phase-3 CARDIO-TTransform trial of Wainua failed to achieve its primary endpoint. Based on this news, the Company’s ADS’s fell by 5.7% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260722690221/en/